Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 7Thoracic 4Sarcoma 2Endocrine 2CNS 2Breast 2Plasma cell 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Prostatic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Suramin × Breast × Clear all
NCT00054028 2015-03-17

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
31 enrolled 16 charts
Breast

Breast Neoplasms

NCT00003038 2011-08-03

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Completed
BreastEndocrineGastrointestinalGenitourinary

Breast Neoplasms, Colonic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡